[Clinical functional study of a new delayed-action preparation of "once a day" anhydrous theophylline in patients with chronic obstructive bronchopneumopathy]. / Studio clinico funzionale su una nuova preparazione ritardo di teofillina anidra "once a day" in pazienti con broncopneumopatia cronica ostruttiva.

A new long-acting theophylline formulation for once-daily administration has been tried in twenty patients with flare-ups of chronic obstructive bronchopulmonary disease (COPD). Clinical results were good and untoward side effects were not observed. Theophylline blood level was tested on the first day and once steady state had been achieved, and was always within the therapeutic range.

[Effectiveness and tolerance of a new molecule with secreto-dynamic activity: nesosteine]. / Efficacia e tollerabilità di una nuova molecola ad attività secretodinamica: la nesosteina.

232 patients with acute or chronic respiratory disorders characterized by increased secretion, were included in an open multicentre trial to evaluate the tolerability and the activity of a new molecule with secreto-dynamic action, nesosteine. The drug was administered orally at the dose of 900 mg/day for two consecutive weeks. The incidence of side effects (11.6%) was comparable to that observed in studies carried out on molecules with similar activity. Undesirable reactions were found mainly at the gastrointestinal level. Side effects were slight/moderate in most cases; only 3 patients abandoned treatment. Nesosteine therapeutic activity was highly valid; cough and expectorate were favourably affected by treatment. The drug, by restoring the natural characteristics of excreate viscoelasticity, favored a better mucociliary clearance and a more incisive cough expelling action. The activity/tolerability ratio was judged excellent/good by the investigator in 83% of the patients treated.